PT-141 (Bremelanotide) in Adolescents Ages 12 to 17: Off-Label Use, Safety, and What the Evidence Actually Shows

What Is Bremelanotide (PT-141) and How Was It Approved?

Bremelanotide is a synthetic cyclic heptapeptide melanocortin receptor agonist, sold under the brand name Vyleesi, approved by the FDA on June 21, 2019 [1]. It works on the central nervous system, binding MC1R, MC3R, and MC4R receptors in brain regions that modulate sexual desire. The approval was specifically for premenopausal adult women diagnosed with acquired, generalized hypoactive sexual desire disorder (HSDD).

The approval was based on two Phase 3 randomized controlled trials. Neither enrolled anyone under 18.

The RECONNECT Trials

The RECONNECT program enrolled 1,267 premenopausal women across two identical trials (Study 301 and Study 302). Participants self-administered 1.75 mg bremelanotide subcutaneously as needed, at least 45 minutes before anticipated sexual activity. Both studies required participants to be adults; adolescents were excluded by design [2].

The primary endpoint was change from baseline in the Female Sexual Function Index desire domain score combined with the Female Sexual Distress Scale-Desire/Arousal/Orgasm score. Statistically significant improvements were observed (P<0.001 for both co-primary endpoints in the pooled analysis), but effect sizes were modest. Roughly 25% of women on active drug versus 17% on placebo reported a clinically meaningful response [2].

FDA Label Scope

The Prescribing Information for Vyleesi explicitly states the drug is indicated for premenopausal adult women only [1]. There is no pediatric labeling. No dosing guidance for anyone under 18 exists anywhere in the approved label or in FDA supplemental applications.

Why Adolescents Ages 12 to 17 Are Categorically Outside the Evidence Base

The short answer: this population was never studied.

No Pediatric Trials Exist

A search of ClinicalTrials.gov using the term "bremelanotide" retrieves 14 registered studies as of January 2025. Zero of those studies enrolled participants under 18. The FDA has not issued a Written Request or a Pediatric Research Equity Act (PREA) mandate requiring the sponsor, AMAG Pharmaceuticals (now Palatin Technologies), to study bremelanotide in adolescents [3]. PREA mandates pediatric studies only when a new drug is approved for an indication that also affects children in meaningful numbers. HSDD, as defined in adults, is not a recognized pediatric diagnosis under current DSM-5-TR criteria [4].

DSM-5-TR and Adolescent Sexual Diagnosis

The DSM-5-TR recognizes female sexual interest/arousal disorder and HSDD-equivalent constructs only in adults. Sexual response patterns in adolescents ages 12 to 17 are still developing neurobiologically. Applying an adult diagnostic construct to this age group lacks clinical validity, and using a pharmacologic agent approved on that adult construct has no logical basis in this population [4].

Melanocortin System Development in Adolescence

The melanocortin system, particularly MC4R signaling in the hypothalamus, is actively involved in the hormonal and metabolic changes of puberty [5]. Exogenous agonism of these receptors during active pubertal development carries theoretical risks that have never been characterized. Animal studies in developing rodents show that MC4R stimulation influences the hypothalamic-pituitary-gonadal (HPG) axis, which governs pubertal progression [5]. Whether bremelanotide disrupts HPG axis maturation in human adolescents is entirely unknown, because the studies were never done.

Safety Profile in Adults and What It Implies for Adolescents

Understanding the adult safety data is the starting point for reasoning about adolescent risk.

Cardiovascular Effects

The most clinically significant adverse effect of bremelanotide in adults is transient blood pressure elevation. In the RECONNECT trials, mean systolic blood pressure increased by approximately 6 mmHg and mean diastolic by approximately 3 mmHg within 12 hours of each dose [2]. This effect resolved within 12 hours in most participants, but the FDA required a contraindication in patients with known cardiovascular or cerebrovascular disease for exactly this reason [1].

Adolescents with undiagnosed or subclinical cardiovascular conditions (congenital heart disease, undiagnosed hypertension, arrhythmias) represent a population with higher-than-recognized cardiovascular risk relative to the screened adult trial population. That 6 mmHg average increase in adults masks a distribution in which some individuals saw much larger spikes. In a 14-year-old with an undetected bicuspid aortic valve or primary hypertension, such spikes carry a materially different risk profile.

Nausea and Emesis

Nausea was the most common adverse event in adult trials, reported in approximately 40% of patients receiving 1.75 mg subcutaneous bremelanotide versus 1% on placebo [2]. Severe nausea requiring dose discontinuation occurred in about 13% of active-drug participants. In a 12 to 17-year-old with lower body weight and a potentially lower threshold for melanocortin-mediated nausea, this adverse effect profile may be worse, not better.

Hyperpigmentation

Focal hyperpigmentation, particularly facial hyperpigmentation, was observed in 1% of women in the adult trials with repeated dosing [1]. The mechanism is agonism of MC1R in melanocytes. Adolescents with higher baseline skin sensitivity and longer expected lifetime of drug exposure would carry greater cumulative pigmentation risk than a 42-year-old using the drug for a finite period.

Drug Interactions

Bremelanotide slows gastric emptying and may reduce the absorption of orally co-administered medications [1]. Adolescents who take oral contraceptives, antibiotics, or psychiatric medications would need interaction counseling that has never been studied in this age group. The prescribing information instructs patients to take any oral medications at least one hour before bremelanotide injection for this reason.

Ethical and Legal Dimensions of Off-Label Prescribing to Minors

Off-label prescribing is legal in the United States. Physicians routinely prescribe medications off-label in pediatric populations, particularly when no approved pediatric option exists. But that practice is justified only when three conditions are present: a plausible biological rationale, some level of safety data in or near the target population, and a clinical need that cannot be addressed by approved alternatives.

The Three-Condition Test

Bremelanotide fails all three conditions in adolescents ages 12 to 17.

First, the biological rationale is absent. HSDD as defined in the adult RECONNECT trials requires a stable prior baseline of sexual desire followed by acquired loss. An adolescent who has never established adult sexual function cannot, by definition, have "acquired" loss of it. The diagnostic prerequisite does not map onto the adolescent phenotype.

Second, there are zero safety data in this age group, in any study, anywhere. The FDA's own pharmacovigilance database (FAERS) contains no pediatric case series for bremelanotide, and no published pharmacokinetic data in patients under 18 exist [6].

Third, no clinical need exists that bremelanotide could legitimately address in this population. Sexual health concerns in adolescents are addressed through psychological counseling, treatment of underlying conditions (depression, hormonal dysregulation, trauma), and age-appropriate behavioral health interventions. None of those require a melanocortin agonist.

Prescriber Liability

A physician who prescribes bremelanotide to a 12 to 17-year-old faces significant liability exposure. The American Academy of Pediatrics' framework for off-label prescribing in children and adolescents requires that clinicians document that benefits outweigh risks based on available evidence [7]. When no evidence exists, that documentation is impossible. Informed consent in minors is legally complex, and assent from a minor combined with parental consent does not insulate a prescriber from liability when harm occurs in the complete absence of safety data.

What Conditions in Adolescents Might Superficially Resemble the Adult HSDD Presentation

Some clinicians encountering adolescents reporting low sexual desire may be tempted to reach for bremelanotide by analogy to adult HSDD. That analogy fails at every clinical step, but knowing what conditions actually cause low desire in adolescents is important.

Common Causes of Low Sexual Desire in Ages 12 to 17

Depression is the leading cause. A 2021 meta-analysis in JAMA Pediatrics (N=80,879) found that depressive disorders affected approximately 13% of adolescents globally [8]. SSRIs, the first-line treatment for adolescent depression, independently reduce sexual desire as an adverse effect, creating a situation where the symptom may be iatrogenic rather than primary.

Hormonal dysregulation, including polycystic ovary syndrome (PCOS), hypothyroidism, and hyperprolactinemia, may suppress sexual desire in adolescents. Each has specific, evidence-based treatment that does not involve melanocortin agonism.

Trauma history, including sexual trauma, is a significant contributor to absent or reduced sexual interest in adolescents. Trauma-focused cognitive behavioral therapy (TF-CBT) has strong RCT support in this population and is the appropriate intervention [9].

Appropriate Referral Pathways

Any adolescent presenting with concerns about sexual desire or function should be referred to a board-certified adolescent medicine specialist or a pediatric-trained mental health provider. The Society for Adolescent Health and Medicine and the American Academy of Pediatrics have published guidance on adolescent sexual health that does not mention pharmacologic augmentation of desire in this age group [7].

What Clinicians and Patients Should Know About Bremelanotide's Regulatory Future

The FDA's Rare Pediatric Disease program and the Best Pharmaceuticals for Children Act (BPCA) could theoretically prompt future study of bremelanotide in adolescents if a qualifying pediatric indication were identified. None has been identified, and no sponsor has proposed one.

Current Regulatory Status

As of January 2025, the FDA label for Vyleesi (bremelanotide injection, 1.75 mg/0.4 mL) has not been updated to include any pediatric population. The FDA's Orange Book lists no pediatric exclusivity for this compound [1]. The drug's patent exclusivity period and market dynamics make a sponsor-initiated pediatric program unlikely without regulatory compulsion, and no such compulsion is forthcoming given the absence of a qualifying pediatric indication.

Palatin Technologies Pipeline

Palatin Technologies continues to study melanocortin receptor agonists in adult populations, including bremelanotide for male sexual dysfunction and PL-8177 for inflammatory bowel disease. None of these programs involve pediatric or adolescent subjects, and the IBD program targets MC1R rather than the MC4R pathway relevant to sexual function [10].

Practical Guidance for Clinicians Encountering Off-Label Requests

Physicians working in telehealth, direct-to-consumer hormone therapy, or integrative medicine may encounter requests to prescribe bremelanotide to minors. The appropriate clinical response is refusal, accompanied by a clear explanation and appropriate referral.

Documentation Recommendations

Document the request, the rationale for declining, and the referral pathway offered. The American Medical Association's Code of Medical Ethics Section 5.2 addresses off-label prescribing and requires that physicians use sound clinical judgment based on evidence. That standard cannot be met for bremelanotide in anyone under 18.

Compounded PT-141

A separate concern: compounded bremelanotide (PT-141) is sold through peptide pharmacies and online platforms without a prescription in some jurisdictions. A 2022 FDA warning letter cited multiple compounding pharmacies for producing bremelanotide outside of federal compounding standards [6]. Adolescents seeking compounded PT-141 through these channels face not only the same pharmacologic risks as any other user, but also the added risks of uncontrolled compounding quality, variable dosing, and the absence of any medical oversight. These products are not approved and do not carry the safety monitoring infrastructure of the branded Vyleesi product.

Clinicians should counsel families that "peptide PT-141" and "Vyleesi" refer to the same active molecule. Neither is appropriate for ages 12 to 17.

Summary of the Evidence Position

The evidence base for bremelanotide use in adolescents ages 12 to 17 is precisely zero randomized controlled trials, zero pharmacokinetic studies in this age group, zero guideline endorsements, and zero approved indications. The drug's mechanism involves active modulation of a receptor system (MC4R) that governs ongoing pubertal development. Its most consistent adverse effect, transient hypertension, carries amplified risk in an age group with higher rates of undetected cardiovascular anomaly.

The Endocrine Society's clinical practice guideline on female sexual dysfunction, updated in 2019, does not mention bremelanotide in any pediatric context and restricts its discussion to premenopausal adults [11]. The International Society for the Study of Women's Sexual Health (ISSWSH) process-of-care consensus document similarly limits bremelanotide discussion to adults ages 18 and over [12].

For any clinician considering this drug for an adolescent patient: the correct dose of bremelanotide in a 12 to 17-year-old is 0 mg.